<div id="readability-page-1">ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) is one of the stocks that will double in 2026. On December 8, Wells Fargo raised the firm’s price target on Oric Pharmaceuticals to $25 from $19 and maintained an Overweight rating on the shares. Although enozertinib has previously been overshadowed by ORIC-944, the intriguing data presented at ESMO Asia is […]</div>

ORIC

<p>富国银行将 ORIC Pharmaceuticals 的目标股价从 19 美元上调至 25 美元，并维持 “增持” 评级，原因是 Enozertinib 在 ESMO Asia 的数据表现令人鼓舞</p>

由于 Enozertinib 在 ESMO 亚洲会议上发布了引人注目的数据，ORIC Pharmaceuticals（ORIC）股价飙升，促使富国银行提高了其估值